Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…
Primary source cited
Last reviewed
In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…
Primary source cited
Last reviewed
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
LEAP-012: transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (The Lancet). DOI 10.1016/S0140-6736(24)02575-3.
Eligibility varies — review trial criteria.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.